H. Lynn Starr, MD, FAAP

Adverse Events Affecting Readiness for Discharge From the Clinical Setting After Esketamine Nasal Spray Administration

Objective: To describe clinical findings in patients considered not ready for discharge from clinical sites 2 hours after administration of esketamine nasal spray (ESK).

Leah Aluisio , PhD;

David Williamson , PhD, MBA;

Ella Daly , MB, BCh, BAO;

Michelle Han , PharmD;

Sheldon Preskorn , MD;

Jagadish Gogate , PhD;

H. Lynn Starr , MD, FAAP;

Andrew Winokur , MD, PhD;

11/22/2019

Impact of Treatment With Esketamine Nasal Spray in Patients With Treatment Resistant Depression and Comorbid Anxiety: A Post-hoc Pooled Analysis of the TRANSFORM 1 and 2 Trials

Purpose: To evaluate the impact of esketamine (ESK) nasal spray in patients with treatment-resistant depression (TRD) and comorbid anxiety.

Ibrahim Turkoz , PhD;

Ella Daly , MB, BCh, BAO;

Stephane Borentain , MD;

Madhukar Trivedi , MD;

Michael Thase , MD;

Jaskaran Singh , MD;

Giacomo Salvadore , MD;

Maggie Fedgchin , PharmD;

H. Lynn Starr , MD, FAAP;

A. John Rush , MD;

11/22/2019

Esketamine Nasal Spray Tolerability Trends During Post-Dose Monitoring in Patients With Treatment-Resistant Depression

Objective: This post hoc analysis assessed (1) whether the first-week incidence of adverse events (AEs) considered most commonly linked to the duration of the post-dose monitoring period ...

Mary Petrillo , PharmD;

Jagadish Gogate , PhD;

H. Lynn Starr , MD, FAAP;

Jennifer Kern Sliwa , PharmD, BCPP;

Ella Daly , MB, BCh, BAO;

David Williamson , PhD, MBA;

Lewis Manera , MS;

03/01/2019